HOWARD LESLIE LEVINE
Pharmacy in Rockville Centre, NY

6818672, Nov 16, 2004

Jul 24, 2002

10/089796

William J. Bologna - Paris, FR
Dominique De Ziegler - Paris, FR
Howard L. Levine - Oceanside NY

Columbia Laboratories, Inc. - Livingston NJ

A01N 3302

514653, 514654, 514967, 424430, 424433, 424434

The present invention concerns compositions and methods for using a -adrenergic agonist for treating endometriosis, for treating infertility, and for improving fertility. The present invention further concerns formulating such a composition or method in such a way as to provide therapeutically sufficient levels of the -adrenergic agonist locally while avoiding adverse systematic concentrations in the host, thereby minimizing or avoiding adverse side effects.

6248358, Jun 19, 2001

Aug 23, 1999

9/379310

William J. Bologna - Paris, FR
Howard L. Levine - Oceanside NY
Philippe Cartier - Paris, FR
Dominique de Ziegler - Paris, FR

Columbia Laboratories, Inc. - Rockville Centre NY

A61K 920, A61F 200, A61F 606, A61F 926

424465

A bioadhesive tablet wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the tablet, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the tablet is available for absorption (bioavailable).

7709026, May 4, 2010

Oct 24, 2002

10/278910

William J. Bologna - Paris, FR
Howard L. Levine - Oceanside NY, US

Columbia Laboratories, Inc. - Livingston NJ

A61K 9/14

424486

The invention relates to a pharmaceutical vaginal composition for treating or preventing vaginal infections. The composition includes a synergistic mix of a bioadhesive, extended release formulation that decreases the pH and that contains a peroxide in an amount sufficient to increase oxygen concentration without sterilizing the vagina or substantially killing the normally-desired local vaginal flora. The invention also relates to a method of treating or preventing vaginal infections in a patient comprising inserting vaginally an amount of the pharmaceutical vaginal composition in an amount sufficient to decrease the pH and increase oxygen concentration without sterilizing the vagina or substantially killing the normally-desired local vaginal flora.

7153845, Dec 26, 2006

Apr 24, 2003

10/421840

Howard L. Levine - Oceanside NY, US
William J. Bologna - Paris, FR
Philippe J. Cartier - Paris, FR
Dominique De Ziegler - Geneva, CH

Columbia Laboratories, Inc. - Livingston NJ

A61K 31/33, A61K 31/553, A61K 31/554

514183, 51421102

A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).

2007003, Feb 8, 2007

May 11, 2006

11/431611

Howard Levine - Oceanside NY, US
William Bologna - Paris, FR
Dominique De Ziegler - Geneva, CH

A61K 9/22

424468000

A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).

2004023, Nov 25, 2004

Feb 17, 2004

10/778151

Howard Levine - Oceanside NY, US
William Bologna - Paris, FR
Dominique De Ziegler - Geneva, CH

A61K009/14

424/486000

The invention relates to a pharmaceutical composition for vaginal administration of a treating agent normally associated with undesired side effects at detrimental blood levels. The composition releases the treating agent at a rate to achieve local tissue concentrations without such detrimental blood levels by using a therapeutically effective amount of the treating agent and a bioadhesive, cross-linked water swellable, but water-insoluble polycarboxylic acid polymer. Using this composition and the method of treatment provides sufficient local levels of the drug to provide therapeutic efficacy, but avoids many untoward adverse events. The invention also relates to a pharmaceutical composition for use during menses that includes a treating agent and a bioadhesive, cross-linked water swellable, but water-insoluble polycarboxylic acid polymer.

5985861, Nov 16, 1999

Nov 4, 1996

8/743153

Howard L. Levine - Oceanside NY
William J. Bologna - New York NY

Columbia Laboratories, Inc. - Aventura FL

A61K 3156

514170

The present invention provides a method of treating or reducing ischemia or incidence of cardiovascular events by administering progesterone. Progesterone, unlike synthetic progestins, has been demonstrated to supplement, rather than to decrease, the beneficial effects of estrogen therapy on myocardial ischemia in females.

6054447, Apr 25, 2000

Feb 1, 1999

9/240610

Howard L. Levine - Oceanside NY
William J. Bologna - New York NY

Columbia Laboratories, Inc. - Aventura FL

A61K 3156

514177

The present invention provides a method of treating or reducing ischemia or incidence of cardiovascular events by administering progesterone. Progesterone, unlike synthetic progestins, has been demonstrated to supplement, rather than to decrease, the beneficial effects of estrogen therapy on myocardial ischemia in females.

2008018, Jul 31, 2008

Sep 4, 2007

11/849862

Howard L. Levine - Oceanside NY, US
William J. Bologna - Paris, FR
Dominique De Zeigler - Geneva, CH

A61K 31/554, A61K 31/165, A61P 13/00, A61P 29/00, A61K 31/195

51421107, 514626, 514570

The invention relates to a pharmaceutical composition for relieving pelvic pain or infertility associated with uterine dysrhythmia. The composition includes a locally-administered anti-dysrhythmic treating agent and a bioadhesive extended-release carrier. The composition may be delivered in an extended release formulation that includes a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer, such as polycarbophil. The treating agent may be a local anesthetic, such as lidocaine. The invention also relates to a method of treating or preventing pelvic pain, or treating or improving infertility, by inserting a mixture of an anti-dysrhythmic treating agent and a bioadhesive carrier into the vagina of the patient to be treated.

6126959, Oct 3, 2000

Sep 1, 1998

9/145172

Howard L. Levine - Oceanside NY
William J. Bologna - New York NY
Dominique de Ziegler - Paris, FR

Columbia Laboratories, Inc. - Aventura FL

A61F 1302, A61F 606

424434

The present invention teaches a composition comprising a. beta. -adrenergic agonist in a bioadhesive carrier. Preferably, the composition comprises terbutaline in polycarbophil. The present invention additionally teaches the local administration of a. beta. -adrenergic agonist for the purpose of treating or preventing dysmenorrhea or premature labor. Using this composition and the method of treatment provides sufficient local levels of the drug to provide therapeutic efficacy, but avoids many untoward adverse events.